NeOnc's Two-Front War on Brain Cancer Gains Global Foothold with Abu Dhabi Nod

DALLAS, TX – June 17, 2026 – Development-stage innovator NeOnc Technologies Holdings (NASDAQ: NTHI) has secured a critical beachhead in its mission to treat aggressive brain cancers, receiving Investigational New Drug (IND) authorization from the Department of Health – Abu Dhabi. The clearance for its oral drug candidate, NEO212, marks the company's first international regulatory approval and signals a significant acceleration of its global strategy.

This move establishes a parallel clinical development pathway outside the United States, a strategic advantage that many experts believe could de-risk and expedite the company’s journey to market. As NeOnc continues its discussions with the U.S. Food and Drug Administration (FDA), the Abu Dhabi approval provides a new front for generating crucial clinical data, underscoring a broader trend where emerging biotech hubs are becoming pivotal players in the global race for medical innovation.

A Strategic Beachhead Beyond the FDA

The authorization from Abu Dhabi is more than a procedural milestone; it's a validation of NeOnc's platform and a testament to its management's expansive vision. The approval allows the company to move forward with studies for NEO212, its oral therapy for glioblastoma and other aggressive brain tumors, in the United Arab Emirates. This follows the successful completion of a Phase 1 dose-escalation study in the U.S., which established 610 mg as the recommended dose for Phase 2 trials.

While patient enrollment in the UAE is contingent on subsequent approvals from local institutional review boards, the initial green light from the Department of Health is a powerful enabler. "Many experts view the parallel regulatory tracks as a potentially important strategic advantage as the company seeks to accelerate global development efforts," as noted in company communications. This dual-track approach allows NeOnc to navigate different regulatory landscapes simultaneously, potentially gathering diverse patient data and mitigating the risks associated with relying on a single regulatory body.

Furthermore, this development aligns with Abu Dhabi's ambitious strategy to position itself as a global hub for life sciences and medical research. NeOnc has also submitted applications for its other key asset, NEO100, in the UAE, signaling a deep commitment to the region. If those are also approved, the company will have a substantial clinical footprint in a geography eager to foster cutting-edge research, potentially creating a synergistic relationship that benefits both the company and the region's healthcare ecosystem.

Rewriting the Rules of Brain Drug Delivery

At the heart of NeOnc's strategy is a formidable scientific challenge: the blood-brain barrier (BBB). This natural defense mechanism is notoriously effective at preventing therapeutics from reaching brain tumors in sufficient concentrations, rendering many otherwise promising drugs ineffective. NeOnc’s entire platform is engineered to overcome this fundamental obstacle.

The company's pipeline is led by two distinct but complementary assets. NEO212, the subject of the Abu Dhabi approval, is a novel oral bioconjugate that chemically links perillyl alcohol with temozolomide, the current chemotherapy standard-of-care for glioblastoma. The design is intended to act as a Trojan horse, using the perillyl alcohol molecule to shuttle the potent chemotherapy across the BBB more effectively. Preclinical data is compelling, suggesting NEO212 could achieve approximately three times greater brain exposure than temozolomide administered alone. Early clinical data from the Phase 1 study has already shown encouraging signs of durable disease stabilization in heavily pretreated patients, a significant finding in a population with few viable options.

Its other flagship candidate, NEO100, takes a different route. It is a patented intranasal formulation of proprietary perillyl alcohol designed for direct nose-to-brain delivery, bypassing the BBB altogether. This program has reached a pivotal moment, having recently completed enrollment in its Phase 2a study for recurrent high-grade gliomas. The company is now on the cusp of multiple data events expected later this year. The anticipation is palpable, particularly given prior clinical observations that reported tumor remission in approximately 24% of recurrent glioblastoma patients treated with NEO100. In a disease where any response is a victory, such a figure has captured significant attention from investors and clinicians alike.

Together, NEO212 and NEO100 represent a sophisticated, two-pronged assault on brain cancer. One enhances the delivery of a proven chemotherapy agent, while the other offers a novel, non-systemic delivery route. This dual approach diversifies the company's risk and expands its potential applicability across different patient populations and stages of the disease.

Insider Confidence Meets Market Momentum

A compelling scientific narrative is essential for any development-stage biotech, but it's the confluence of science and financial validation that often signals a company's transition from speculative to strategic. In NeOnc's case, the financial underpinnings appear to be strengthening in lockstep with its clinical progress.

One of the most telling indicators is the pattern of insider buying from its own leadership. Chairman, President, and CEO Amir Heshmatpour has personally invested more than $500,000 in open-market purchases of NeOnc stock in recent weeks. This brings his total personal investment over the past year to nearly $1 million. While not a guarantee of future success, sustained, significant insider buying is widely interpreted by investors as a powerful vote of confidence from those with the most intimate knowledge of the company's prospects.

This internal optimism is being mirrored by growing external validation. Major financial institutions, including Bank of America, State Street, and Barclays, have appeared on regulatory filings as institutional holders. The presence of such Wall Street heavyweights reflects an increasing awareness of the company's potential and provides a layer of stability. This institutional interest is further supported by a flexible financial position, which includes access to a $75 million at-the-market facility and a $10 million line of credit. For a company advancing multiple costly clinical programs simultaneously, this financial runway is critical.

The company’s profile has also been bolstered by growing recognition for its leadership, including Heshmatpour’s inclusion in USA Today's list of "Top Entrepreneurs Going Into 2026." With a key data readout for NEO100 on the horizon and a Type B End-of-Phase 1 meeting with the FDA pending for NEO212, NeOnc is approaching a series of potentially transformational catalysts. The combination of regulatory progress, a differentiated scientific platform, and robust financial backing has positioned the company as a significant emerging player in the high-stakes field of neuro-oncology.